Management of childhood onset nephrotic syndrome

Pediatrics

Volumn 124, Issue 2, 2009, Pages 747-757

  Gipson, Debbie S ^a   Massengill, Susan F ^b   Yao, Lynne ^c   Nagaraj, Shashi ^d   Smoyer, William E ^e,f   Mahan, John D ^f   Wigfall, Delbert ^g   Miles, Paul ^h   Powell, Leslie ^a   Lin, Jen Jar ^d,i   Trachtman, Howard ^j   Greenbaum, Larry A ^k  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

^d WAKE FOREST BAPTIST HEALTH   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f NATIONWIDE CHILDREN S HOSPITAL   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h AMERICAN BOARD OF PEDIATRICS   (United States)

ⁱ EAST CAROLINA UNIVERSITY   (United States)

^j SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^k EMORY UNIVERSITY   (United States)

more..

Author keywords

Kidney disease; Nephrosis; Pediatric; Proteinuria

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBIN III; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LEVAMISOLE; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLIN G; PNEUMOCOCCUS VACCINE; PREDNISONE; STEROID; THIAZIDE DIURETIC AGENT;

ACUTE KIDNEY FAILURE; ANTICOAGULANT THERAPY; ARTICLE; BACTERIAL PERITONITIS; BODY MASS; CATARACT; CELLULITIS; CHILDHOOD DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIET THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY VEIN THROMBOSIS; MORBIDITY; MORTALITY; NEPHROSIS; NEPHROTIC SYNDROME; OBESITY; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; SIDE EFFECT; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANTINEOPLASTIC AGENTS; BIOPSY; CHILD; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; MYCOPHENOLIC ACID; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; PREDNISONE;

EID: 67749101270     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-1559     Document Type: Article

References (93)

1. Churg J, Habib R, White RH. Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet. 1970;760(1):1299 -1302
2. The primary nephrotic syndrome in children: identification of patients with minimal change nephrotic syndrome from initial response to prednisone-a report of the International Study of Kidney Disease in Children. J Pediatr. 1981;98(4):561-564
3. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome: a report of Arbeitsgemeinschaft fü r Pä diatrische Nephrologie. Lancet. 1979;1(8113):401- 403
4. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fü r Pä diatrische Nephrologie. Lancet. 1988;1(8582):380 -383
5. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fü r Pä diatrische Nephrologie. Eur J Pediatr. 1993;152(4):357-361
6. Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol. 1999;13(1):13-18
7. Lichtig C, Ben-Izhak O, On A, Levy J, Allon U. Childhood minimal change disease and focal segmental glomerulosclerosis: a continuous spectrum of disease? Pathologic study of 33 cases with longterm follow-up. Am J Nephrol. 1991;11(4):325-331
8. Harris KM, Gordon-Larsen P, Chantala K, Udry JR. Longitudinal trends in race/ethnic disparities in leading health indicators from adolescence to young adulthood. Arch Pediatr Adolesc Med. 2006; 160(1):74-81
9. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136(5): 664-672
10. Gipson DS, MacHardy N, Massengill S, et al. Variability in childhood onset nephrotic syndrome management in North America. 2009 In press
11. Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111(6 pt 1):1416 -1421
12. Clarkson MR, Meara YM, Murphy B, Rennke HG, Brady HR. Collapsing glomerulopathy: recurrence in a renal allograft. Nephrol Dial Transplant. 1998;13(2):503-506
13. Niaudet P, Gagnadoux MF, Broyer M. Treatment of childhood steroid-resistant idiopathic nephrotic syndrome. Adv Nephrol Necker Hosp. 1998;28:43- 61
14. Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol. 1999;13(9):824-827
15. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2005;(1):CD001533
16. Hiraoka M, Tsukahara H, Matsubara K, et al. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis. 2003;41(6):1155-1162
17. Ksiazek J, Wyszynska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr. 1995;84(8):889-893
18. Hoyer PF, Brodehl J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A-a prospective, randomized trial. J Am Soc Nephrol. 2006;17(4):1151-1157
19. Hiraoka M, Tsukahara H, Haruki S, et al. Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. Kidney Int. 2000;58(3):1247-1252
20. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early-report of the international study of kidney disease in children. J Pediatr. 1979;95(2):239 -243
21. Latta K, von S, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001;16(3):271-282
22. Hogg RJ, Fitzgibbons L, Bruick J, et al. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1(6):1173-1178
23. Gregory MJ, Smoyer WE, Sedman A, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol. 1996;7(4):543-549
24. Kitano Y, Yoshikawa N, Tanaka R, Nakamura H, Ninomiya M, Ito H. Ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1990;4(5):474-477
25. Abeyagunawardena AS, Dillon MJ, Rees L, van't Hoff W, Trompeter RS. The use of steroid-sparing agents in steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2003;18(9):919 -924
26. Hulton SA, Jadresic L, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome. Pediatr Nephrol. 1994;8(4):404-407
27. Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. J Paediatr Child Health. 2007;43(5):337-341
28. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatr Nephrol. 1997;11(4):418-422
29. Fujieda M, Ishihara M, Morita T, et al. Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol. 2008;69(3):179 -184
30. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994;125(6 pt 1): 981-986
31. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol. 2004;19(1):101-104
32. Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol. 2003;18(7):661- 664
33. Gipson DS, Chin H, Presler TP, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol. 2006;21(3):344 -349
34. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061-1068
35. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet. 1974;2(7878):423- 427
36. Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid-resistant nephrotic syndrome: a controlled study. Am J Dis Child. 1988;142(9):985-988
37. Hymes LC. Steroid-resistant, cyclosporine-responsive, relapsing nephrotic syndrome. Pediatr Nephrol. 1995;9(2):137-139
38. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7(1):56-63
39. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43(6):1377-1384
40. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide: a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol. 1994;8(1):1-3
41. Tarshish P, Tobin JN, Bernstein J, Edelmann CM. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10(5):590 -593
42. Feld SM, Figueroa P, Savin V, et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis. 1998;32(2):230 -237
43. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2(5):906 -913
44. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol. 2007;2(2):326 -333
45. Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol. 2008;23(3):481- 485
46. Tahzib M, Frank R, Gauthier B, Valderrama E, Trachtman H. Vitamin E treatment of focal segmental glomerulosclerosis: results of an open-label study. Pediatr Nephrol. 1999;13(8):649-652
47. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10(11):1963-1974
48. Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr. 2003;143(1):89 -97
49. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19(1):45-50
50. Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2006;21(7):967-972
51. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67(3): 799-812
52. Hanevold CD. Acute renal failure during lisinopril and losartan therapy for proteinuria. Pharmacotherapy. 2006;26(9):1348 -1351
53. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after firsttrimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-2451
54. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 suppl 4th report):555-576
55. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis: a report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13(2):159 -165
56. Kü ster S, Mehls O, Seidel C, Ritz E. Blood pressure in minimal change and other types of nephrotic syndrome. Am J Nephrol. 1990;10(suppl 1):76-80
57. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol. 2005;16(suppl 1): S58 -S63
58. Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics. 1993;91(6):1142-1146
59. Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura H. Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1993;7(3):249 -252
60. Donatti TL, Koch VH, Fujimura MD, Okay Y. Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. Pediatr Nephrol. 2003;18(8):789 -795
61. Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003;18(8):783-788
62. Hegarty J, Mughal MZ, Adams J, Webb NJ. Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome. Kidney Int. 2005;68(5):2304 -2309
63. Rü th EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005;147(2):202-207
64. Berns JS, Gaudio KM, Krassner LS, et al. Steroid-responsive nephrotic syndrome of childhood: a long-term study of clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth. Am J Kidney Dis. 1987;9(2):108 -114
65. Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood: effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila). 1988;27(8):387-392
66. Foster BJ, Shults J, Zemel BS, Leonard MB. Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2006;21(7):973-980
67. Merritt RJ, Hack SL, Kalsch M, Olson D. Corticosteroid therapy-induced obesity in children. Clin Pediatr (Phila). 1986;25(3):149 -152
68. Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol. 2004;19(7):744 -748
69. Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl. 1999;71:S113-S116
70. Valdivielso P, Moliz M, Valera A, Corrales MA, Sanchez-Chaparro MA, Gonzalez-Santos P. Atorvastatin in dyslipidaemia of the nephrotic syndrome. Nephrology (Carlton). 2003;8(2):61- 64
71. Holmes KW, Kwiterovich PO Jr. Treatment of dyslipidemia in children and adolescents. Curr Cardiol Rep. 2005;7(6):445- 456
72. Tain YL, Lin G, Cher TW. Microbiological spectrum of septicemia and peritonitis in nephrotic children. Pediatr Nephrol. 1999;13(9):835- 837
73. Krensky AM, Ingelfinger JR, Grupe WE. Peritonitis in childhood nephrotic syndrome: 1970 -1980. Am J Dis Child. 1982;136(8):732-736
74. Hingorani SR, Weiss NS, Watkins SL. Predictors of peritonitis in children with nephrotic syndrome. Pediatr Nephrol. 2002;17(8):678-682
75. Gorensek MJ, Lebel MH, Nelson JD. Peritonitis in children with nephrotic syndrome. Pediatrics. 1988;81(6):849-856
76. Matsell DG, Wyatt RJ. The role of I and B in peritonitis associated with the nephrotic syndrome of childhood. Pediatr Res. 1993;34(1):84-88
77. Milner LS, Berkowitz FE, Ngwenya E, Kala U, Jacobs D. Penicillin resistant pneumococcal peritonitis in nephrotic syndrome. Arch Dis Child. 1987;62(9):964 -965
78. McIntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health. 1998;34(4):314 -317
79. Mehls O, Andrassy K, Koderisch J, Herzog U, Ritz E. Hemostasis and thromboembolism in children with nephrotic syndrome: differences from adults. J Pediatr. 1987;110(6):862- 867
80. Citak A, Emre S, Sairin A, Bilge I, Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. 2000;14(2):138 -142
81. Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974 -1996). Pediatr Nephrol. 2000;15(1-2):74 -78
82. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest. 1994;93(1):204 -211
83. Deshpande PV, Griffiths M. Pulmonary thrombosis in steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2005;20(5):665- 669
84. Gangakhedkar A, Wong W, Pitcher LA. Cerebral thrombosis in childhood nephrosis. J Paediatr Child Health. 2005;41(4):221-224
85. Papachristou FT, Petridou SH, Printza NG, Zafeiriou DI, Gompakis NP. Superior sagittal sinus thrombosis in steroid-resistant nephrotic syndrome. Pediatr Neurol. 2005;32(4):282-284
86. Jones CL, Hebert D. Pulmonary thrombo-embolism in the nephrotic syndrome. Pediatr Nephrol. 1991;5(1):56 -58
87. Share A, Uzun O, Blackburn ME, Gibbs JL. Prolonged local infusion of streptokinase in pulmonary artery thrombosis with nephrotic syndrome. Pediatr Nephrol. 1996;10(6):734 -736
88. Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr. 1998;132(4):575-588
89. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92(2):223-228
90. Quien RM, Kaiser BA, Deforest A, Polinsky MS, Fisher M, Baluarte HJ. Response to the varicella vaccine in children with nephrotic syndrome. J Pediatr. 1997;131(5):688-690
91. Alpay H, Yildiz N, Onar A, Temizer H, Ozcay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2002;17(3):181-183
92. Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr. 2003;142(2):145-148
93. American Academy of Pediatrics. Active and passive immunization. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book. 27th ed. Elk Grove Village: American Academy of Pediatrics. 2006:9-40